Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
| ▸ | BBOX1 | O75936 | 2/20 | 0.46 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CCKAR | P32238 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 2/20 | 0.41 |
| ▸ | PYGL | P06737 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468146 | 0.91 | ERAP1 (0.48) | WDR5BBOX1EGLN1FTOALDH1A1 | |
| SCHEMBL2405015 | 0.81 | PLK1 (0.60) | BBOX1EGLN1FTOALDH1A1CCKAR | |
| SCHEMBL9831137 | 0.81 | PLK1 (0.60) | BBOX1EGLN1FTOALDH1A1CCKAR | |
| SCHEMBL27987430 | 0.80 | BBOX1 (0.45) | WDR5BBOX1EGLN1FTOALDH1A1 | |
| SCHEMBL12467289 | 0.79 | EGLN1 (0.49) | WDR5EGLN1MEN1KMT2ATACR3 | |
| SCHEMBL28633025 | 0.77 | WDR5 (0.68) | WDR5ALDH1A1MEN1KMT2AELANE | |
| SCHEMBL12467113 | 0.77 | MMP9 (0.45) | EGLN1ALDH1A1MEN1KMT2ATACR3 | |
| SCHEMBL485937 | 0.76 | BBOX1 (0.43) | BBOX1EGLN1FTOALDH1A1CCKAR | |
| SCHEMBL17070768 | 0.76 | WDR5 (0.59) | WDR5ALDH1A1MEN1KMT2A | |
| SCHEMBL2240626 | 0.75 | WDR5 (0.81) | WDR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283479-B2 | CXCR2 inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-10-09 | — | — | US | disclosed |
| US-20110184177-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-07-28 | — | — | US | disclosed |
| US-7919628-B2 | 2-[(1-Benzyloxy-naphthalene-2-carbonyl)-amino]-2-methyl-propionic acid; inhibitors of chemokine receptors; treatment or prophylaxis of acute and chronic inflammatory diseases such as atherosclerosis, ischemic or reperfusion injuries, chronic obstructive pulmonary disease, asthma, rheumatoid arthritis | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-04-05 | — | — | US | disclosed |
| US-20080090854-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184177-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | WDR5 4268/4885BBOX1 759/4885EGLN1 1944/4885 |
| US-20080090854-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | WDR5 4268/4885BBOX1 759/4885EGLN1 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.